Department of Otolaryngology, Massachusetts Eye and Ear, Boston, MA, USA.
Center for Surgery and Public Health, Brigham and Women's Hospital, Boston, MA, USA.
Int J Pediatr Otorhinolaryngol. 2021 Mar;142:110627. doi: 10.1016/j.ijporl.2021.110627. Epub 2021 Jan 13.
Pediatric tonsillectomy is one of the most common surgical procedures performed in the United States. The safety of ibuprofen use after surgery is debated given concern for increased bleeding. The primary objective of this study was to compare the rate of post-tonsillectomy hemorrhage requiring operative management in patients who received ibuprofen perioperatively vs. patients who did not.
Retrospective cohort study of patients 0-18 years old who underwent tonsillectomy with or without adenoidectomy (T&A) with recorded inpatient medication administration data at a single tertiary care institution from 1/2005-1/2019. The association between perioperative medication administration and return to operating room (OR) for control was evaluated using multivariable logistic regression adjusted for patient demographics and operative indication. Secondary outcomes evaluated included the time to operative bleed when it occurred.
A total of 4098 patients with a median age of 6 years old (IQR 4-10) underwent T&A over the study period. The overall rate of post-tonsillectomy hemorrhage requiring OR was 3.37% (n = 138/4098). After adjustment for confounders, the odds of bleeding requiring OR did not differ significantly between the ibuprofen (OR 1.16, 95% CI (0.76, 1.74), 3.55%, n = 41/1,156, p = 0.47) and non-ibuprofen groups (3.30%, n = 97/2942). The median time to bleeding requiring OR was postoperative day 6.5 (IQR6-8) in the ibuprofen group and day 6 (IQR 3-8) in the non-ibuprofen group.
No difference in post-tonsillectomy hemorrhage requiring OR was observed between patients receiving perioperative ibuprofen versus those patients not receiving this medication. Additional research is required to definitively determine a safe dose and interval for ibuprofen administration following tonsillectomy.
小儿扁桃体切除术是美国最常见的手术之一。由于担心出血增加,布洛芬在手术后使用的安全性存在争议。本研究的主要目的是比较接受围手术期布洛芬治疗与未接受布洛芬治疗的患者在扁桃体切除术后发生需要手术治疗的出血的发生率。
这是一项回顾性队列研究,纳入了在一家三级医疗机构接受扁桃体切除术(T&A)的 0-18 岁患者,这些患者的住院期间用药数据有记录,研究时间为 2005 年 1 月至 2019 年 1 月。使用多变量逻辑回归评估围手术期药物使用与返回手术室(OR)进行控制之间的关联,并对患者人口统计学和手术指征进行了调整。评估的次要结局包括发生手术性出血时的出血时间。
在研究期间,共有 4098 名中位年龄为 6 岁(IQR 4-10)的患者接受了 T&A。总体扁桃体切除术后出血需要 OR 的发生率为 3.37%(n=138/4098)。在调整混杂因素后,布洛芬组(OR 1.16,95%CI(0.76,1.74))和非布洛芬组(OR 3.30%,n=97/2942)发生需要 OR 的出血的可能性无显著差异。布洛芬组需要 OR 的出血的中位时间为术后第 6.5 天(IQR6-8),而非布洛芬组为第 6 天(IQR 3-8)。
接受围手术期布洛芬治疗与未接受该药物治疗的患者在需要 OR 的扁桃体切除术后出血方面无差异。需要进一步的研究来确定在扁桃体切除术后使用布洛芬的安全剂量和间隔。